Security key
10806X102
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 193,809,015
- Total 13F shares
- 188,818,044
- Share change
- +3,515,109
- Total reported value
- $8,154,464,813
- Put/Call ratio
- 20%
- Price per share
- $43.18
- Number of holders
- 357
- Value change
- +$171,957,099
- Number of buys
- 222
- Number of sells
- 139
Report period
Q2 2025
Institutions
357
Top holders
10
BBIO full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
BridgeBio Pharma, Inc. SEC filings
BridgeBio Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 10806X102
Recent filing periods:
Top shareholders of BBIO - BridgeBio Pharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. |
13D/G
3/4/5
|
10%+ Owner |
7%
|
13,260,971
|
$476,864,517 | -$215,760,000 | 12 May 2025 | |
| VIKING GLOBAL INVESTORS LP |
3/4/5
13F
|
10%+ Owner · Company |
9.6%
|
18,555,375
|
$816,436,500 | -$154,000,000 | 27 Jun 2025 | |
| Kohlberg Kravis Roberts & Co. L.P. |
13F
|
Company |
9.9%
|
19,260,971
|
$665,851,767 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.7%
|
14,900,145
|
$515,098,014 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.9%
|
13,357,496
|
$461,768,637 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
3.7%
|
7,171,399
|
$251,725,223 | — | 31 Mar 2025 | |
| Aisling Capital Management LP |
13F
|
Company |
3.1%
|
6,068,125
|
$209,775,081 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
5,749,619
|
$198,764,329 | — | 31 Mar 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
3%
|
5,731,000
|
$198,120,670 | — | 31 Mar 2025 | |
| Capital Research Global Investors |
13F
|
Company |
2.4%
|
4,667,402
|
$161,352,087 | — | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
2%
|
3,800,457
|
$131,381,798 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
3,502,894
|
$121,122,935 | — | 31 Mar 2025 | |
| Laurion Capital Management LP |
13F
|
Company |
1.5%
|
2,978,167
|
$102,955,234 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.5%
|
2,931,033
|
$101,325,811 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
1.4%
|
2,800,000
|
$96,796,000 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.4%
|
2,684,146
|
$92,790,927 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
2,223,308
|
$76,859,757 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.1%
|
2,206,163
|
$76,267,056 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
1.1%
|
2,198,514
|
$76,002,629 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
1.1%
|
2,175,799
|
$75,217,380 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.1%
|
2,090,268
|
$72,415,185 | — | 31 Mar 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
1%
|
2,000,000
|
$69,140,000 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.97%
|
1,887,763
|
$65,259,967 | — | 31 Mar 2025 | |
| SC US (TTGP), LTD. |
13F
|
Company |
0.96%
|
1,860,364
|
$64,312,783 | — | 31 Mar 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.95%
|
1,850,039
|
$63,955,848 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.84%
|
1,625,755
|
$56,202,350 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.77%
|
1,500,558
|
$51,874,290 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.77%
|
1,498,619
|
$51,807,279 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.72%
|
1,401,513
|
$48,450,304 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.66%
|
1,286,847
|
$44,486,301 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.66%
|
1,282,229
|
$44,326,657 | — | 31 Mar 2025 | |
| NORGES BANK |
13F
|
Company |
0.64%
|
1,244,955
|
$43,038,094 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.6%
|
1,164,967
|
$40,274,000 | — | 31 Mar 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.59%
|
1,148,292
|
$39,696,453 | — | 31 Mar 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
0.59%
|
1,145,491
|
$39,599,624 | — | 31 Mar 2025 | |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC |
13F
|
Company |
0.58%
|
1,129,592
|
$39,049,995 | — | 31 Mar 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.58%
|
1,120,933
|
$38,750,654 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.54%
|
1,041,935
|
$36,016,546 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.53%
|
1,027,488
|
$35,520,279 | — | 31 Mar 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
0.5%
|
962,883
|
$33,286,865 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.49%
|
946,850
|
$32,732,592 | — | 31 Mar 2025 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
0.47%
|
913,200
|
$31,569,324 | — | 31 Mar 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.47%
|
908,135
|
$31,394,227 | — | 31 Mar 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.44%
|
857,922
|
$29,658,000 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.44%
|
843,321
|
$29,153,607 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.43%
|
838,358
|
$28,982,036 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.41%
|
800,075
|
$27,658,593 | — | 31 Mar 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
0.4%
|
769,301
|
$26,594,733 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.39%
|
760,474
|
$26,289,586 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.38%
|
739,704
|
$25,571,567 | — | 31 Mar 2025 |
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock (BBIO) as of Q2 2025
As of 30 Jun 2025,
BridgeBio Pharma, Inc. - Common Stock (BBIO) was held by
357 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
188,818,044 shares.
The largest 10 holders included
VIKING GLOBAL INVESTORS LP, VANGUARD GROUP INC, BlackRock, Inc., Kohlberg Kravis Roberts & Co. L.P., JANUS HENDERSON GROUP PLC, FARALLON CAPITAL MANAGEMENT LLC, Aisling Capital Management LP, STATE STREET CORP, Capital Research Global Investors, and Frazier Life Sciences Management, L.P..
This page lists
358
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
302
Q2 2025 holders
357
Holder diff
55
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.